| Press
Releases |
| |
|
- APRIL
20, 2004
BIO
Mid-America VentureForum
Dr.
Stephen Porter has been invited to speak at the BIO Mid-America
VentureForum which is The Regional Venture Conference
for the financial community and biotech companies in America’s
Heartland. He is scheduled to speak on Tuesday, May 4th,
at 10:00 AM. This conference is being held at the Chase
Park Plaza Hotel in St. Louis, Missouri.
For more information, please contact the hotel at 1-877-587-2427
|
- APRIL
20, 2004
6th
Annual C21 BioVentures Conference
Mr.
Steve Sensoli has been invited to speak at the 6th Annual
C21 BioVentures Conference on Wednesday, May 5th, at 2:30
PM, in Stream A. The mission of this conference is to
educate in the bioscience industry the trends that are
driving its growth and development in the 21st century
and for leading investors and company executives to meet
and exchange ideas and to review business plans of innovative
new companies in the fields of biotechnology, informatics,
medical devices and healthcare services. This conference
is being held at the Paradise Point Resort and Spa in
San Diego, California.
For
more information, please call 1-831-464-7105 or 1-831-464-4230
|
|
|
- June
20,
2003 - Brentwood, TN
VDDI
garners $1.6 million grant for oral anthrax antibiotic.
The Brentwood-based biopharmaceutical development firm says
the funding will go toward developing a NADS inhibitor as
an oral antibiotic for anthrax and other gram positive bacteria.
(Click
here for full article)
|
- June
12 ,
2003 - Brentwood, TN and Princeton, NJ
VDDI
Pharmaceuticals, a biopharmaceutical development company,
today announced it has acquired a portfolio of patents and
patent applications from Interlink Biotechnologies LLC (ILB)
that will enable the successful implementation of medical
peptides.
(Click here for full article)
|
- June
12, 2003
- Brentwood, TN and
Birmingham, AL
VDDI
Pharmaceuticals, a biopharmaceutical development company,
and the University of Alabama at Birmingham today announced
receipt of allowance for a patent from the United States
Patent and Trademark Office for a NADs inhibitor (nicotinamide
adenine dinculeotide synthetase) to treat hospital acquired
fungal infections.
(Click here for full article)
|
- February
13,
2003 - Kalamazoo,
MI
WMU
Drug Development Pact Will Bring Tennessee Firm to Michigan.
A Tennessee firm will develop and commercialize a recent
Pharmacia Corp. drug patent donation to Western Michigan
University, and the firm will join the growing cluster of
life science companies to open research facilities in Kalamazoo.
(Click
here for full article)
|
- February
12 ,
2003 - Nashville,
TN
Tennessee
Firm Taking Pharmacia Drug Candidate to Market.
Officials from Brentwood-based VDDI Pharmaceuticals announced
today that the company has been awarded exclusive worldwide
license rights for Pharmacia drug candidate, Xemilofiban
(xemi). (Click here for full article)
|
- October
8, 2002 - Franklin,
TN
Cool Springs
Life Sciences Center Groundbreaking.
The Cool Springs Life Sciences Center will be home to research
and development-focused operations for biotech, pharmaceutical
and medical device companies and support services, providing
companies within the same industry an environment of collaboration
and shared resources. (click
here for a fact sheet)
|
- May 7, 2002
- Nashville
Business Journal
VDDI
Pharmaceuticals teams with ILB on peptide development
VDDI
Pharmaceuticals of Brentwood has agreed to collaborate with
a Princeton, N.J., firm in the development of peptides for
use in humans and animals. As part of the agreement, VDDI
Pharmaceuticals will have access to InterLink Biotechnologies'
patents and information related to peptides, which can be
used to make pharmaceuticals.
(click
here for full article)
|
- May 7, 2002
- Princeton, N.J. & Brentwood, TN.--Business Wire
InterLink
Biotechnologies Announces Agreement with Virtual Drug Development
for New Peptide Pharmaceuticals.
InterLink Biotechnologies LLC (ILB) and VDDI Pharmaceuticals
today announced a research and development collaboration
for the development of certain peptides for medical uses
in humans and animals. (click
here for full article)
|
- February
26, 2002 - Research Triangle Park, NC and Brentwood TN
Paradigm Genetics, Inc. (Nasdaq: PDGM) and VDDI Pharmaceuticals
today announced a research and development collaboration
for the development of antibiotics for the treatment of
gram-positive bacterial infections. Under the terms of the
agreement, VDDI Pharmaceuticals will support Paradigm's
research and development efforts, as well as pay potential
royalties. In addition, Paradigm will have the option to
make an unspecified equity investment in VDDI Pharmaceuticals;
further specific financial details were not disclosed. (click
here for full article)
|
| |
- January
2, 2002 - The Tennessean
State industry fighting terrorism
Porter's company, Virtual Drug Development Inc., hopes that
within 36 to 48 months it can provide the U.S. military
with an anthrax treatment that has fewer side effects than
two primary treatments now in use — the antibiotic
Cipro and a vaccine that is in short supply. (click
here for full article)
|
| |
- June
23, 2001 - NashvillePost.com
A Brentwood biotechnology firm awaiting a $23 million
federal research grant expects to finish developing an anthrax
antidote that could have a potential market of as much as
$650 million. (click here for full
article)
|
| |
- August
2, 2000 - Brentwood, TN
A $135,590 U.S. Department of Health and Human Services
grant will enable Virtual Drug Development Inc. to continue
its search for an antibiotic treatment of the chemical weapon
anthrax, U.S. Rep. Bart Gordon announced. (click
here for full article)
|
| |
- October
11, 2000 - US House of Representatives Testimony
VDDI Pharmaceuticals was formed in order to capitalize on
the opportunity to develop early stage pharmaceuticals.
The Company licenses attractive product development opportunities
from academic institutions, biotech firms and pharmaceutical
companies. (click here for full article)
|
| |
| Media |
| |
|
| |
|
| |
|
| |
|
| |
|
